GENITOURINARY CANCERS

A study analyzes the impact of spacers on biochemical control in prostate cancer patients, revealing significant differences in outcomes.

Discover the most anticipated abstracts on renal cell carcinoma and bladder cancer at the 2025 ESMO Congress in Berlin.

Researchers uncover that rectal spacers significantly enhance cancer cure rates, reducing treatment failure by 50% in prostate cancer patients.

Discover how rectal spacers revolutionize prostate cancer treatment by reducing side effects and enhancing radiation dose delivery for better patient outcomes.

New findings reveal that combining niraparib with abiraterone significantly extends progression-free survival in patients with HRR-altered metastatic prostate cancer.

Recent analysis reveals that rectal spacers significantly lower recurrence rates in prostate cancer patients undergoing radiation therapy, enhancing treatment outcomes.

A phase 2 trial reveals PSMA-PET–guided salvage radiotherapy significantly enhances cancer control in patients with prostate cancer post surgery.

Chandler H. Park, MD, discusses NCCN treatment regimens for patients with metastatic bladder cancer.

Explore the latest advancements in muscle-invasive bladder cancer treatment, including immunotherapy and novel therapies enhancing patient outcomes.

Petros Grivas, MD, PhD, discusses how the JAVELIN Bladder 100 trial established avelumab as standard maintenance therapy for advanced bladder cancer.

Prostate cancer advancements highlight genetic mutations' impact on therapy and family health, emphasizing early treatment strategies for better outcomes.

Dr Daniel Petrylak discusses groundbreaking advancements in prostate cancer treatment, including genetic mutations, PARP inhibitors, and innovative PROTAC therapies.

A new treatment combination shows promise in extending progression-free survival for advanced prostate cancer patients, highlighting innovative cancer therapies.

Discover groundbreaking advancements in prostate cancer treatment with innovative PROTAC drugs, promising new trials, and enhanced therapy effectiveness.

Navigating the complex landscape of prostate cancer treatment sequencing is crucial for maximizing patient outcomes and survival rates.

KIM-1 emerges as a promising biomarker for renal cell carcinoma, enhancing prognosis and treatment decisions in kidney cancer management.

Belzutifan shows improved quality-adjusted survival in advanced renal cell carcinoma compared with everolimus, enhancing patient quality of life and treatment outcomes.

Combination therapy of casdatifan and cabozantinib shows promising efficacy and manageable safety in patients with advanced clear cell renal cell carcinoma.

Joseph Jacob, MD, discusses gemcitabine intravesical delivery as a highly effective treatment for high-risk, BCG-unresponsive bladder cancer, achieving an 82% response rate.

Joseph Jacob, MD, discusses the how the recent FDA approval of the gemcitabine intravesical system offers a radically different treatment approach for patients with bladder cancer.

Promising results emerge from a clinical trial combining IDE397 and sacituzumab govitecan for treating MTAP-deleted urothelial cancer, showcasing safety and efficacy.

The FDA approves Inlexzo, a groundbreaking treatment for bladder cancer, offering hope for patients unresponsive to traditional therapies.

The FDA approves a long-acting injectable for advanced prostate cancer, offering a convenient quarterly dosing option and improved patient care.

A groundbreaking study reveals how the Decipher Prostate Genomic Classifier personalizes chemotherapy decisions for metastatic prostate cancer patients, enhancing treatment outcomes.

Alpha1H shows promising results in treating non-muscle-invasive bladder cancer, demonstrating significant tumor response and a strong safety profile in clinical trials.